Mesoblast Ltd Files 6-K Report

Ticker: MEOBF · Form: 6-K · Filed: Dec 20, 2024 · CIK: 1345099

Mesoblast LTD 6-K Filing Summary
FieldDetail
CompanyMesoblast LTD (MEOBF)
Form Type6-K
Filed DateDec 20, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulatory-filing, foreign-private-issuer

TL;DR

MESO files 6-K, check ASX for Dec 18 update.

AI Summary

On December 18, 2024, Mesoblast Limited announced a new release filed with the Australian Securities Exchange. This filing is a Form 6-K report for the month of December 2024, detailing information as of December 18, 2024. The company is incorporated in Australia and its principal executive offices are located in Melbourne.

Why It Matters

This filing provides an update on Mesoblast Limited's regulatory and corporate activities, which could impact investor understanding of the company's current status.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of a foreign private issuer and does not appear to contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The Form 6-K filing is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of December 2024, containing a new release announcement filed with the Australian Securities Exchange on December 18, 2024.

Who is the Chief Executive Officer of Mesoblast Limited?

Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.

Where are Mesoblast Limited's principal executive offices located?

Mesoblast Limited's principal executive offices are located at Level 38, 55 Collins Street, Melbourne, 3000, Australia.

What is the SEC file number for Mesoblast Limited?

The SEC file number for Mesoblast Limited is 001-37626.

Does Mesoblast Limited file annual reports under Form 20-F or Form 40-F?

Mesoblast Limited indicates it files annual reports under Form 20-F.

Filing Stats: 212 words · 1 min read · ~1 pages · Grade level 17.3 · Accepted 2024-12-19 18:27:02

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Paul Hughes Paul Hughes Company Secretary Dated December 19, 2024 INDEX TO EXHIBITS Item 99.1 Press release of Mesoblast Ltd, dated December 18, 2024.

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing